New drug cocktail aims to protect kidneys in High-Risk patients

NCT ID NCT06942910

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 study tests whether a combination of two drugs, zibotentan and dapagliflozin, works better than dapagliflozin alone at reducing protein leakage in urine for adults with chronic kidney disease. About 224 participants will receive either the combo or the single drug. The main goal is to see if the combo lowers protein levels more effectively, which could mean better kidney protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zibotentan and Dapagliflozin combination
What this could lead to: If successful, this could offer a new treatment option to slow kidney damage in people with chronic kidney disease and high protein levels in urine.
What could go wrong: This is an early Phase 2 trial with only 224 participants, so results may not apply to everyone. The combination may cause side effects or not work better than the existing drug alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates